Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(25.0%)
Early Phase 1
1(25.0%)
N/A
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 2(1)
Early Phase 1(1)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07196358Not ApplicableCompleted

Topical Heparin for Prevention of Hypertrophic Scarring in Split-Thickness Skin Graft Donor Sites

Role: lead

NCT04723524Phase 2Completed

Jinhua Qinggan Granules in the Treatment of COVID-19

Role: collaborator

NCT04700228Phase 4Unknown

Comparison of Doses of Dexmedetomidine With Bupivacaine in Caudal Block for Duration of Analgesia in Paediatric Infraumblical Surgeries.

Role: lead

NCT04646317Early Phase 1Unknown

Hemodynamic Stability of Dexmedetomidine in Hypertensive Patients Undergoing Laparoscopic Cholecystectomy

Role: lead

All 4 trials loaded